Figure 1.
Gene expression analysis of selected upregulated genes and immunohistochemical expression of FXR in pancreatic cancer tissues with and without LN metastasis. (A) Upregulated gene analysis between pancreatic cancer tissues with and without LN metastasis by real-time PCR. (B) Real-time PCR validation of microarray data. For each sample, the amount of target and endogenous reference was determined from the appropriate standard curve. The target amount was then divided by an endogenous reference (GAPDH) amount to obtain a normalised target value. The black columns represent the mean of fold (Group II/Group I) values obtained in DNA microarray; the grey columns represent the mean of fold (Group II/Group I) values obtained in real-time PCR; *P<0.05. (C) Overexpression of FXR in pancreatic cancer tissues with LN metastasis. The FXR intensity on tissues was evaluated by immunohistochemical staining. (a) A representative negative staining in pancreatic cancer tissues without LN metastasis. Magnification, × 200. (b) A representative positive staining in pancreatic cancer tissues with LN metastasis. Magnification, × 200. (D) Kaplan–Meier analysis of overall survival for patients with ductal adenocarcinoma (n=34). Farnesoid X receptor expression-positive cases (n=15) had significantly poorer prognosis than expression -negative cases (n=19; P=0.0227, log-rank test).